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Opinion statement
There are currently no disease-modifying treatments for progressive supranuclear
palsy (PSP) or corticobasal degeneration (CBD), and no approved pharmacological or
therapeutic treatments that are effective in controlling their symptoms. The use of
most pharmacological treatment options are based on experience in other disorders
or from non-randomized historical controls, case series, or expert opinion. Levodopa
may provide some improvement in symptoms of Parkinsonism (specifically bradyki-
nesia and rigidity) in PSP and CBD; however, evidence is conflicting and where
present, benefits are often negligible and short lived. In fact, Bpoor^ response to
levodopa forms part of the NINDS-SPSP criteria for the diagnosis of PSP and
consensus criteria for the diagnosis of CBD (Lang Mov Disord. 20 Suppl 1:S83–91,
2005; Litvan et al. Neurology. 48:119–25, 1997; Armstrong et al. Neurology.
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80(5):496–503, 2013). There is some evidence that intrasalivery gland botulinum
toxin is useful in managing problematic sialorrhea and that intramuscular botulinum
toxin and baclofen are helpful in reducing dystonia, including blepharospasm.
Benzodiazepines may also be useful in managing dystonia. Myoclonus may be
managed using levetiracetam and benzodiazepines. Pharmacological agents licensed
for Alzheimer’s disease (such as acetylcholinesterase inhibitors and N-Methyl-D-
aspartate receptor antagonists) have been used off-label in PSP, CBD, and other
tauopathies with the aim of improving cognition; however, there is limited evidence
that they are effective and risk of adverse effects may outweigh benefits. The use of
atypical antipsychotics for behavioural symptoms is not recommended in the elderly
or those with demetia associated conditions and most antipsychotics will worsen
Parkinsonism. Antidepressants may be useful for behavioral symptoms and depres-
sion but are often poorly tolerated due to adverse effects. In the absence of an
effective drug treatment to target the underlying cause of CBD and PSP, manage-
ment should focus on optimizing quality of life, relieving symptoms and assisting
patients with their activities of daily living (ADL). Patients should be managed
by a multidisciplinary team consisting of neurologists, physiotherapists (PT),
occupational therapists (OT), speech and language therapists (SALT), dieticians,
ophthalmologists, psychologists, and palliative care specialists.
Introduction
Progressive supranuclear palsy (PSP) or Steele-
Richardson-Olszewski syndrome is a progressive
neurodegenerative disorder characterized by pro-
gressive gait disturbance (with poor balance and
early falls) and a supranuclear gaze palsy (typically
downward gaze)[1–4]. Other features may include
axial and limb rigidity, motor eyelid disorders,
pseudobulbar signs (dysarthria and dysphagia),
and frontal/subcortical dementia [1–3]. Patients
typically present in their 5th–7th decade [5, 6].
The mean onset age is 63 years and the mean
survival is 6–9 years [2, 3, 5, 6]. The incidence of
PSP is estimated to be between 1.4 and 5.3 per
100,000 [2, 3]. Neuropathologically, PSP is associ-
ated with the deposition of hyperphosphorylated
tau as neurofibrillary tangles, neuropil threads,
and fibrillary gliosis in the pallidum, subthalamic
nucleus, red nucleus, striatum, substantia nigra,
pontine tegmentum, oculomotor nucleus, medulla,
and dentate nucleus [3, 7, 8].
Corticobasal degeneration (CBD) is a progres-
sive neurodegenerative disease characterized by pro-
gressive asymmetrical rigidity and apraxia [9, 10•,
11]. Symptoms and presentation vary and patients
may experience dystonia, myoclonus, tremor, alien
limb phenomenon, motor speech disorders, eye
movement disturbance, cortical dementia, and cor-
tical sensory loss [10•, 12–14]. Patients typically
present in their 6th or 7th decades (mean age of
onset 64) and mean survival is 6 to 7 years [11,
15–17]. The incidence of CBD is estimated to be
between 0.62 and 0.92 per 100,000 with a preva-
lence of 4.9–7.3 per 100,000 [9]. CBD is associated
with accumulation of aggregates containing the
four- repeat i soforms of tau [12, 13, 18] .
Neuropathologically, CBD is defined by asymmet-
rical parietal and frontal cortical degeneration, with
neurofilament protein-positive ballooned neurons
and tau-positive astrocytic plaques and coiled bod-
ies in oligodendrocytes [11]. However, the clinical
syndrome of CBD is increasingly reported with
other underlying pathologies such as Alzheimer’s
disease (AD), frontotemporal lobar degeneration,
PSP, dementia with Lewy bodies, and Creutzfeldt-
Jakob disease; therefore, patients are often de-
scribed as having a corticobasal syndrome (CBS)
until a definitive diagnosis of CBD can be made
[19].
The diagnoses of PSP and CBD are difficult due
to the lack of specific biomarkers and is further
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complicated by the fact that many of the clinical
features of PSP and CBD overlap with each other
and with other neurodegenerative diseases, includ-
ing multiple system atrophy (MSA) and disorders
within the frontotemporal dementia spectrum (be-
havioral variant FTD—bvFTD and primary progres-
sive aphasia—PPA) [12, 13, 15, 18].
Disease-modifying therapies for PSP and CBD
have targeted tau pathology. Davunetide is thought
to decrease tau phosphorylation by promoting mi-
crotubule stability; however, in a randomized
double-blind placebo-controlled trial in 313 pa-
tients with PSP, although well tolerated, davunetide
was ineffective, showing no improvement in the
progressive supranuclear palsy rating scale or
Schwab and England activities of daily living
s c a l e [ 2 0 ] . G l y c o g en s y n t h a s e k i n a s e - 3
(GSK-3) is a kinase believed to play a role in the
hyperphosphorylation of the tau protein. However,
in a randomized, double-blind, placebo-controlled
trial of 146 patients with PSP Tideglusib, a GSK-3
inhibitor, although well tolerated, was not shown
to be clinically effective [21••]. Lithium has also
been shown to regulate GSK-3; however, in a ran-
domized, single-blind, placebo-controlled trial of
71 patients with AD, lithium was not shown to
have any treatment effect on GSK-3 activity and
did not support the notion that it reduced tau
hyperphosphorylation [22]. Riluzole is considered
neuroprotective and has been shown to block gluta-
matergic neurotransmission in the central nervous
system and is well tolerated and prolongs survival
in patients with amyotrophic lateral sclerosis; how-
ever, in a randomized, double-blind, placebo-
controlled trial of patients with PSP, riluzole was
not shown to improve survival in PSP and similarly
did not improve survival in patients with MSA [23,
24••, 25, 26]. Lisuride was also shown to have no
significant effect in the treatment of PSP [6].
In the absence of approved pharmacological
treatments for PSP and CBD, management should
be based on relieving symptoms and assisting pa-
tients with their activities of daily living [3, 9, 27].
Advanced care planning and non-pharmacological
supportive therapies remain paramount in the
management of PSP and CBD. Most patients will
be trialed on L-DOPA and amantadine, although
there is limited evidence for benefit some patients
may expe r i en c e mode s t improvemen t in
Parkinsonism [15, 32, 61]. Botulinum toxin is
helpful in reducing dystonia and in managing
sialorrhoea and is particularly useful for eyelid
dysmotility [23, 30, 31, 57, 60–63].
Advanced care planning should be addressed at
the earliest possible opportunity, and ideally, when
the patient is able (and legally competent) to com-
municate their wishes about their treatment prefer-
ences. Early input by the palliative care team is
advised to explore the patients’ feelings about re-
suscitation status, ceilings of care, and artificial
feeding using radiologically inserted gastrostomy
(RIG) and percutaneous endoscopic gastrostomy
(PEG). Where artificial feeding tubes are sited, de-
cisions should me made about criteria for future
withdrawal. Review by psychologists or psychia-
trists may be helpful where patients exhibit chal-
lenging behaviors. Patient and caregiver education
is important, and patients should be given plenty
of information about relevant support groups. In
some circumstances, patients may need a social
worker who can provide advice about support from
social services.
Diet and lifestyle
Patients with CBD and PSP may suffer from swallowing difficulties, poor
appetite, and gastrointestinal upset leading to malnutrition and weight loss.
Input from speech and language therapists (SALTs) and dieticians is important
to ensure patients maintain a healthy and balanced diet with sufficient calorie
intake. Changes to diet and nutritional supplements may be required.
Caregivers should be educated about how to optimize oral intake to ensure
adequate nutrition and minimize risk of aspiration [28].




Indication Rigidity and bradykinesia
Evidence in the literature A retrospective study of cases from the Queen Square Brain Bank (with a
diagnosis of CBS or pathologically proven CBD) showed that 56 % of patients
taking levodopa experienced mild-to-moderate improvement in their symp-
toms. Of these, 17% developed dystonia and choreiformmovements (level IV)
[18, 29•].
A retrospective study of patients with histologically proven CBD found no
significant or sustained improvement from levodopa (level IV) [11]. Similarly,
a retrospective study of 14 patients with CBD concluded that no patient had a
dramatic response to levodopa [16].
In a retrospective study of 147 patients with a clinical diagnosis of CBD,
levodopa improved Parkinsonism in 24 % (level IV) [30].
An observational study of 26 patients with CBD reported a mild, transient
improvement with levodopa in some patients (level IV) [31].
In a case series of ten patients with PSP, two experienced moderate transient
improvement in symptoms [1]. In another case series of patients with PSP,
levodopa moderately improved akinesia and rigidity (level V) [32].
Standard dose Initially, levodopa 50mg 3–4× daily, with a dopa decarboxylase inhibitor such
as benserazide (as co-beneldopa) or carbidopa (co-careldopa) titrated slowly
according to response, up to 800 mg daily in divided doses.
Main drug interactions Hypertensive crisis with type A MAOIs.
Enhancement of antihypertensive medication effect
Side effects Nausea, vomiting, constipation, dystonia, choreiform movements, palpita-
tions, postural hypotension, on/off episodes, psychosis, depression, and uri-
nary retention [28].
Special points Nausea and vomiting are common and should be treated with a peripheral
dopamine receptor blocker such as domperidone 10 mg TDS.
Levodopa should be coadministered with a dopa decarboxylase inhibitor to avoid
peripheral conversion to dopamine and reduce peripheral adverse effects [28].
Levodopa should not be stopped abruptly.
Class of drug—dopaminergic agents
Amantadine
Indication Bradykinesia and rigidity
Evidence in the literature In a case study of two patients with PSP, amantadine 300 mg daily
improved bradykinesia, rigidity, and range of voluntary lateral eye move-
ments (level V) [32].
In a case series of patients with CBD, amantadine 300 mg daily was given
without improvement (level V) [9]
Standard dose Initially, 100 mg daily, titrated slowly up to 400 mg daily as tolerated. Usually
not recommended after 4 p.m. because of the risk of insomnia.
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Main drug interactions Concomitant use with tramadol, buproprion, and iohexol increases risk of
seizures
Side effects Insomnia and confusion are common. Also, postural hypotension, dizziness,
gastrointestinal upset, dry mouth, headache, anxiety, anorexia, and livedo
reticularis
Special points Warn patients and caregivers of risk of impulse control disorders (excessive
spending, gambling)
This medication should not be stopped abruptly.
Rotigotine
Indication Bradykinesia and rigidity
Evidence in the literature In a study of 51 patients with atypical Parkinson’s syndrome (including CBD and
PSP), transdermal rotigotine was shown to be effective and safe (reflected by an
improvement in the Unified Parkinson’s Disease Rating Scale) (level IV) [22, 23].
Standard dose Transdermal patch delivering 2–4 mg/24 h titrated slowly up to maximum of
16 mg/24 h
Main drug interactions Antagonism of effects with concomitant use of antipsychotics, methyldopa, and
metoclopramide. Use with sodium oxybate or alcohol may cause drowsiness,
dizziness, and confusion.
Side effects Postural hypotension, dry mouth, gastrointestinal upset, drowsiness, dizziness,
excessive daytime sleepiness, dyskinesia, and headache
Special points Warn patients and caregivers of risk of impulse control disorders (excessive
spending, gambling)
This medication should not be stopped abruptly.
Class of drug—antipsychotics
The use of atypical antipsychotics in elderly patients with dementia is associated
with increased mortality and is therefore NOT recommended to treat behav-
ioral symptoms in patients with dementia in associated conditions [33]. Most
anti-psychotics will worsen parkinsonism.
Class of drug—acetylcholinesterase inhibitors
Current evidence for the use of acetylcholinesterase inhibitors for cognitive and
behavioral symptoms in non Alzheimer’s disease dementia is inconclusive, and
risk of adverse effects may outweigh the potential benefits in these patients.
Treatment of these symptoms in CBD and PSP is based on off-label use of these
medications [18]. A randomized, double-blind, placebo-controlled trial of
donepezil in patients with PSP showed improvement in cognition but also
reported a deterioration in ADL and mobility; donepezil was therefore NOT
recommended in this group (level II) [1, 28]. Acetylcholinesterase inhibitors
may also be associated with worsening of symptoms in FTD. In a study of 12
patients with FTD, donepezil was associated with worsening behavior (in-
creased disinhibition and compulsive behavior) and showed no evidence of
improvement in cognitive function or dementia severity (level III) [34, 35] . In a
double-blind study of 36 patients with bvFTD and PPA, galantamine did not
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improve behavioral or language symptoms (level III) [35–37]. In another open-
label study, rivastigmine was shown to improve behavioral symptoms and
caregiver burden but did not slow cognitive decline (level III) [33, 38, 39].
Class of drug—selective serotonin reuptake inhibitors
There are no randomized controlled trials of selective serotonin reuptake in-
hibitors (SSRIs) in CBD or PSP. A number of small studies of SSRIs in FTD have
shown evidence of improvement in behavioral symptoms but no improvement
in cognition [33, 40]. In a study of 35 patients with FTD, treatment with
paroxetine improved repetitive ritualistic behaviors and anxiety in 75 % of
patients (level IV) [41]. Another randomized controlled study of paroxetine in
FTD showed significant improvement in behavioral symptoms (level II) [42].
An open-label trial of paroxetine in eight patients with FTD showed improve-
ment in behavior but deterioration in cognition (level III) [40]. Similarly, in a
double-blind, randomized, controlled cross-over trial of ten patients with
bvFTD, paroxetine was associated with decreased accuracy of paired-associate
learning, reversal learning, and delayed pattern recognition (level II) [40, 43].
Sertraline
Indication Depression
Evidence in the literature In a case study of a patient with CBD, sertraline was shown to significantly
improve depression (reflected by an improvement in the geriatric depression
scale) (level V) [28].
Standard dose Initially 25 mg day titrated slowly to a maximum of 200 mg day
Contraindications Monoamine oxidase inhibitors (MAOIs) should not be taken 2 weeks before or
after treatment with this medication.
SSRIs should not be used in poorly controlled epilepsy or patients with mania.
Pimozide contraindicated
Main drug interactions Risk of serotonin syndrome with concomitant use of St. Johns Wort, MAOIs,
other SSRIs, and serotonin-norepinephrine reuptake inhibitors (SNRIs).
SSRIs affect plasma concentration of some tricyclic antidepressants and anti-
epileptics.
Increased risk of CNS toxicity with tramadol and lithium.
Risk of arrhythmia when administered with drugs that prolong QT interval.
Increased risk of bleeding with clopidogrel, non-steroidal anti-inflammatory
drugs (NSAIDs), or warfarin
Side effects Nausea, dizziness, dry mouth, anorexia, sweating, gastrointestinal disturbance,
insomnia, QT prolongation




Evidence in the literature An open-label study of 15 patients with FTD showed a significant improvement
in the Neuropsychiatric Inventory (NPI) and frontal behavioral inventory with
citalopram (level III) [44].
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Standard dose Twenty-milligram once daily up to 40 mg once daily. However, in elderly,
initiate at 10 mg once daily up to maximum of 20 mg
Contraindications MAOIs should not be taken 2 weeks before or after treatment with this medi-
cation.
SSRIs should not be used in poorly controlled epilepsy or patients with mania.
Pimozide contraindicated
Main drug interactions Risk of serotonin syndrome with concomitant use of St. Johns Wort, MAOIs,
other SSRIs, and SNRIs.
SSRIs affect plasma concentration of some tricyclic antidepressants and anti-
epileptics.
Increased risk of CNS toxicity with tramadol and lithium.
Risk of arrhythmia when administered with drugs that prolong QT interval.
Increased risk of bleeding with clopidogrel, NSAIDs, or warfarin
Side effects Nausea, dizziness, dry mouth, anorexia, sweating, gastrointestinal disturbance,
and insomnia.
Special points Caution in epilepsy, cardiac disease, diabetes mellitus, angle closure glaucoma,
and bleeding disorders.
Class of drug—tricyclic antidepressants
There are no pharmacologically approved treatments for depression in patients
with CBD and PSP; however, tricyclic antidepressants (TCAs) are widely used in
the empirical treatment of depression in Parkinson’s disease (PD) and have
been shown to improve tremor and help improve sialorrhoea and urinary
frequency [45, 46]. They have also been shown to improve behavioral symp-
toms in patients with FTD [40, 47–49].
Amitriptyline
Indication Depression
Evidence in literature In a retrospective study, amitriptyline improved Parkinsonism in a patient with
autopsy-proven PSP (level IV) [50].
In a retrospective study of patients with PSP, amitriptyline was beneficial in
32 % (level IV) [51].
Standard dose Standard recommendations in adult patients are to initiate amitriptyline at
75mg daily in divided doses or as a single dose at bedtime, increasing gradually
as tolerated up to 150–200 mg. However, in elderly patients and those with
concomitant disease, amitriptyline should be initiated at 10–25 mg at night
and gradually titrate upward as tolerated.
Contraindications MAOIs should not be taken 2 weeks before or after treatment with this medi-
cation.
Pimozide contraindicated.
Contraindicated in acute porphyria, manic phase of bipolar disorder, in the
immediate recovery period following MI, and in arrhythmias.
Main drug interactions Risk of serotonin syndrome with concomitant use of St. Johns Wort, MAOIs,
other SSRIs, and SNRIs.
TCAs affect plasma concentration of antiepileptics
Increased risk of CNS toxicity with tramadol.
Risk of arrhythmias when administered with drugs that prolong QT interval, in
particular amiodarone.
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Increased risk of bleeding with clopidogrel, NSAIDs, or warfarin.
Avoid concomitant use of nortriptyline due to risk of hypertension and
arrhythmias.
Side effects Dry mouth, blurred vision, headache, drowsiness, dizziness, weight gain, gas-
trointestinal upset, anxiety, agitation, and QT prolongation.
Special points Avoid in elderly due to risk of confusion and amnesia.
Avoid in liver disease.
On cessation, reduce gradually over 4 weeks to avoid withdrawal symptoms.
Imipramine hydrochloride
Indication Depression
Evidence in the literature In a retrospective study of patients with PSP, imipramine was shown to be
beneficial in 28 % of patients (level IV) [51].
Standard dose Initially, 75 mg daily in divided dose, increased gradually up to 150–200 mg;
however, in elderly, initiate at 10 mg daily and gradually titrate up to 50 mg.
Contraindications MAOIs should not be taken 2 weeks before or after treatment with this medi-
cation.
Pimozide contraindicated.
Contraindicated in acute porphyria, manic phase of bipolar disorder, imme-
diate recovery period following MI, and in arrhythmias.
Main drug interactions Risk of serotonin syndrome with concomitant use of St. Johns Wort, MAOIs,
other SSRIs, and SNRIs.
TCAs affect plasma concentration of antiepileptics.
Increased risk of CNS toxicity with tramadol.
Risk of arrhythmias when administered with drugs that prolong QT interval.
Increased risk of bleeding with clopidogrel, NSAIDs, or warfarin.
Avoid concomitant use of nortriptyline due to risk of hypertension and
arrhythmias.
Side effects Dry mouth, blurred vision, fatigue, flushing, restlessness, palpitations, head-
ache, drowsiness, dizziness, weight gain, gastrointestinal upset, anxiety, agita-
tion, and QT prolongation.
Special points Avoid in elderly due to risk of confusion and amnesia.
Avoid in liver disease.
On cessation, reduce gradually over 4 weeks to avoid withdrawal symptoms.
Clomipramine
Indication Depression and obsessional states
Evidence in the literature In a case series of a patients with bvFTD, clomipramine was shown to improve
compulsive behaviors (level IV) [52].
Standard dose Ten to 25 mg daily, increased gradually up to a maximum dose of 250 mg.
Contraindications MAOIs should not be taken 2 weeks before or after treatment with this medi-
cation.
Pimozide contraindicated.
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Contraindicated in acute porphyria, manic phase of bipolar disorder, in the
immediate recovery period following MI, and in arrhythmias.
Main drug interactions Risk of serotonin syndrome with concomitant use of St. Johns Wort, MAOIs,
other SSRIs, and SNRIs.
May affect plasma concentration of antiepileptics.
Increased risk of CNS toxicity with tramadol.
Risk of arrhythmias when administered with drugs that prolong QT interval.
Increased risk of bleeding with clopidogrel, NSAIDs, or warfarin.
Avoid concomitant use of nortriptyline due to risk of hypertension and
arrhythmias.
Side effects Dry mouth, blurred vision, headache, drowsiness, dizziness, weight gain, gas-
trointestinal upset, anxiety, agitation, QT prolongation, flushing, sweating,
rarely allergic alveolitis.
Special points Avoid in elderly due to risk of confusion and amnesia.
Avoid in liver disease.
On cessation, reduce gradually over 4 weeks to avoid withdrawal symptoms.
Trazodone
Indication Depression and behavioral symptoms
Evidence in the literature Significant improvement in depression was seen following treatment with
trazodone in 20 patients with PD (level III) [53].
A randomized, double-blind, placebo-controlled cross over trial of 26 patients
with FTD demonstrated a significant decrease in the NPI and improvements in
behavior following treatment with trazodone (level II) [40, 48]. These benefi-
cial effects were sustained in an open-label extension of this study (level III) [40,
47]. In another open-label study of 14 patients with FTD, trazodone was shown
to have a dose-dependent effect on behavioral symptoms [40, 49], but it did not
improve cognition (level III) [39, 48].
Standard dose Initially, 150 mg (100 mg in elderly) daily in divided doses (after food) or as a
single dose at bedtime. Increased up to 300 mg daily.
Contraindications MAOIs should not be taken 2 weeks before or after treatment with this medi-
cation.
Pimozide contraindicated.
Contraindicated in acute porphyria, manic phase of bipolar disorder, in the
immediate recovery period following MI, and in arrhythmias.
Main drug interactions Risk of serotonin syndrome with concomitant use of St. Johns Wort, MAOIs,
other SSRIs, and SNRIs.
May affect plasma concentration of antiepileptics.
Risk of arrhythmias when administered with drugs that prolong QT interval.
Side effects Hypertension, myalgia, arthralgia, hypersalivation, dry mouth, gastrointestinal
upset, weight change; blurred vision, palpitations, dyspnea, QT prolongation.
Special points Avoid in elderly due to risk of confusion and amnesia.
Avoid in liver disease.
On cessation, reduce gradually over 4 weeks to avoid withdrawal
symptoms.
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Class of drug—hypnotics and anxiolytics
Diazepam
Indication Dystonia and myoclonus
Evidence in the literature In a study of 147 patients with a clinical diagnosis of CBD, 23 % reported
improvement in myoclonus and 9 % improvement in dystonia following
treatment with benzodiazepines; side effects of somnolence were reported in
26 % (level IV) [30].
Standard dose Two to 15 mg daily in divided doses; can be increased to 60 mg daily (in
divided dose) in spastic conditions.
Contraindications Respiratory depression, sleep apnea, neuromuscular disorders, andmyasthenia.
Main drug interactions Opioids, antidepressants, antipsychotics, and antifungals.
Side effects Fatigue and lethargy are common, also confusion, poor concentration, drowsiness,
dizziness, hypotonia, malcoordination, headache, irritability, and memory loss.
Special points Risk of rebound hypotension and tachycardia on withdrawal.
Clonazepam
Indication Dystonia and myoclonus
Standard dose Five hundred micrograms to 8 mg a day in divided doses if necessary.
Contraindications Respiratory depression, sleep apnea, neuromuscular disorders, andmyasthenia.
Main drug interactions Opioids, antidepressants, antipsychotics, and antifungals.
Side effects Fatigue and lethargy are common, also confusion, poor concentration, drowsiness,
dizziness, hypotonia, malcoordination, headache, irritability, and memory loss.
Special points Risk of dependence and withdrawal.
Zolpidem
Decreased neurotransmission of g-aminobutyric acid (GABA) in the striatum
and globus pallidus is thought to contribute to the symptoms of PSP; therefore,
drugs that act upon the GABAergic systems in the basal ganglia may be helpful
in this condition [54].
Indication Dystonia and myoclonus
Evidence in the literature In a case study of a patient with PSP, zolpidem transiently improved speech,
facial expressions, and fine motor skills. Less marked improvements were seen
with eszopiclone, temazepam, and flurazepam [55].
In another case study of a patient with PSP, zolpidem showed sustained
improvements in motor and bulbar symptoms (reduced saliva pooling; im-
proved speech, swallow, and bradykinesia) (level V) [56].
In a case study of a patient with PSP, a single 10-mg dose of zolpidem improved
akinesia, rigidity, dysarthria, and voluntary eye movements (level V) [54].
Similar results were observed in a double-blind, placebo-controlled cross-over
42 Page 10 of 18 Curr Treat Options Neurol (2016) 18: 42
study of ten patients with probable PSP, with significant improvements in
motor function (lasting up to 2 h) following 5 mg zolpidem (level II) [54].
Standard dose Five to 10 mg at night up to maximum of 60 mg daily
Contraindications Respiratory depression, sleep apnea, neuromuscular disorders, and myasthenia
Main drug interactions Opioids, antidepressants, antipsychotics, and antifungals
Side effects Fatigue and lethargy are common, also confusion, poor concentration, drows-
iness, dizziness, hypotonia, malcoordination, headache, irritability, memory
loss, postural hypotension, and gastrointestinal upset.





Evidence in the literature A case study of a 72-year-old patient with CBD reported reduction in debili-
tating myoclonus (level V) [57].
Standard dose Initially 250 mg a day
Main drug interactions Antidepressants, other antiepileptics, antimalarials, and antipsychotics.
Side effects Depression is common and needs careful monitoring. Also, dizziness, drows-
iness, weakness, fatigue, anxiety, and agitation.
Special points Avoid abrupt withdrawal.
Class of drug—anticholinergics/antimuscarinics
There is no recognized pharmacological treatment approved for hypersalivation
and sialorrhea in CBD and PSP. Evidence is based on off-label use of medica-
tions observed in PD and patients with neurodevelopmental disabilities.
Atropine
Indication Hypersalivation
Evidence in the literature In the NICE full clinical guidance on the management of PD, sublingual 1 %
atropine ophthalmic solution twice daily was suggested as an option for the
management of hypersalivation.
Standard dose One percent atropine ophthalmic solution administered sublingually, one drop
twice daily.
Contraindications Myasthenia gravis, urinary retention, gastrointestinal obstruction.
Side effects Constipation, dry mouth, bradycardia, urinary urgency and retention, visual
disturbance, and photophobia.
Special points Caution in elderly.
Avoid in patients with cognitive impairment, dementia, or hallucinations due
to effects on cognition.
Curr Treat Options Neurol (2016) 18: 42 Page 11 of 18 42
Glycopyrrolate
Indication Hypersalivation
Evidence in the literature In a randomized, double-blind, placebo-controlled cross-over trail of
23 patients with PD, oral glycopyrrolate 1 mg three times daily was
found to be more effective than placebo in reducing sialorrhea (class
II) [58].
A review of treatments by the Movement Disorder Society concluded
that glycopyrrolate was efficacious for the very short-term treatment of
sialorrhea in PD, but there was insufficient evidence for the treatment
of sialorrhea in PD exceeding 1 week (class V) [59]. There is no
specific evidence relating to atypical parkinsonian syndromes.
Standard dose 1 mg TDS orally.
Contraindications Myasthenia gravis.
Side effects Constipation, bradycardia, urinary urgency, retention, visual disturbance, and
photophobia.
Special points Caution in elderly.
Avoid in patients with cognitive impairment, dementia, or hallucinations due
to effects on cognition.
Class of drug—ophthalmic preparations
Acetylcysteine
Indication Dry eyes
Standard dose Apply three to four times daily.
Special points Do not use concomitantly with contact lenses.
Carbomers
Indication Dry eyes
Standard dose Apply three to four times daily or as required.
Special points Do not use concomitantly with contact lenses.
Carmellose solution, hydroxyethyl cellulose, hydroxypropyl guar, hypromellose, liquid paraffin,
paraffin (yellow, soft), polyvinyl alcohol, and sodium hyaluronate
Indication Dry eyes
Standard dose Apply as required.
Special points Do not use concomitantly with contact lenses.
Sodium chloride 0.9 %
Indication Dry eyes
Standard dose Apply as required.
Special points Suitable for contact lens wearers.
42 Page 12 of 18 Curr Treat Options Neurol (2016) 18: 42
Other treatments
Botulinum toxin
Indication Dystonia, including blepharospasm and sialorrhea
Evidence in the literature In a study of 147 patients with clinical diagnosis of CBD, 6 out of 9
patients reported improvement in dystonia following botulinum toxin
therapy (level IV) [30].
In a case study of a patient with CBD, botulinum toxin therapy improved
pain from a flexion deformity (level V) [9].
In an observational study of 26 patients with CBD, all those treated with
botulinum toxin showed symptomatic benefit (reflected by an improve-
ment in the Unified Dystonia Rating Scale) (level III) [31].
Botulinum toxin was also found to be beneficial in the treatment of
sialorrhea in patients with parkinsonian disorders, with 65.22 % of the
patients reporting a transient improvement in their symptoms (level V)
[60].
Botulinum toxin has also shown beneficial effects in patients with bleph-
arospasm and apraxia of eyelid opening (level V) [61–63].
Standard dose Botulinum toxin type A—usually 100–400 units (depending on individual
preparation)
Botulinum toxin type B—usually 5000–10,000 units divided between themost
affected muscles by intramuscular injection.
Contraindications Neuromuscular junction disorders.
Side effects Transient weakness and discomfort at the injection site [18]. Dry mouth,
dyspepsia, dysphagia, neck pain, voice changes, taste disturbance, headache,
and blurred vision.
Special points Side effects of dysphagia may be of greater risk when injecting botu-
linum into the salivary glands for management of sialorrhea in PSP
[61].
Assistive devices
Urinary catheter There is no data in the literature to guide use of urinary catheters in CBDor PSP;
however, they are a useful tool to manage urinary difficulties at the end of life,
reducing caregiver burden and patient discomfort, improving hygiene, and
reducing the risk of skin breakdown.
Prisms
Indication Gaze paresis patients should have an ophthalmology review to determine if
interventions such as prisms could help correct double vision and to exclude
additional pathology.
Special points Patients should not wear prisms continuously.
Patients should register as sight impaired.
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Interventional procedures
Radiologically inserted gastroscopy and percutaneous endoscopic gastroscopy
Evidence in the literature A systematic literature review found no evidence to suggest improved survival
in patients with advanced dementia who underwent PEG insertion for dys-
phagia (level IV) [64]. There have been no studies on survival following PEG or
RIG in CBD or PSP.
Physical/speech/occupational therapy and exercise
Physiotherapy Physiotherapists should be consulted to optimize strength, balance, pos-
ture, coordination, and mobility and to help prevent falls.
Physiotherapists can also provide advice on walking aids, orthotics, and
splints to prevent contractures.
Evidence in the literature In a case study of a patient with CBD, repetition of facilitation exercises
improved hand function and ADL (level V) [29•].
A regular exercise program undertaken over 10 years in a patient with features of
CBD and PSP was shown to decrease falls and maintain mobility, balance, and
strength (level V) [33].
In an observational study of 26 patients with CBS, motor and non-motor
symptoms improved following a combination of physical therapy, phar-
macological therapy, and (low frequency) repetitive transcranial stimula-
tion (level V) [31].
Occupational therapy Occupational therapists should assess patients to identify and minimize
potential hazards, and they can assist in developing skills to promote
independence: providing the necessary tools to assist the patient in their
ADL.
Speech therapy Speech and language therapists can provide solutions and strategies to
help overcome communication and swallowing difficulties in those with
dysphasia, dysarthria, and/or dysphagia. Close monitoring of dysphagia is
essential to help prevent aspiration and maintain adequate oral nutrition
and a healthy weight.
Evidence in the literature In a prospective longitudinal study of 20 patients with PPA, regular
speech and language therapy was shown to slow language decline (level
III) [65].
A study of two patients with PPA showed sustained improvement in
language skills and greater confidence in communication following lex-
ical retrieval training (level IV) [66]. Similar studies have also demon-
strated positive effects following language treatment in patients with
PPA (level IV) [67–69].
Support services
Supportive therapy is the mainstay of management, and contact with
support groups may be of benefit to patients and those who care for
them [3].
42 Page 14 of 18 Curr Treat Options Neurol (2016) 18: 42
PSP Association The PSP Association is a registered charity dedicated to the support of people
with PSP, CBD, and those who care for them. The PSP association provides
information leaflets, telephone, and e-mail advice and hosts support groups
and educational events.
http://www.pspassociation.org.uk
Cure PSP Cure PSP is an organization dedicated to furthering research into neurodegen-
erative diseases. It provides information and support to people with PSP, CBD,
and related conditions, and those caring for them.
http://www.psp.org
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